ClinicalTrials.gg
CompletedNCT05990725ADhopeUpdated Jul 17, 2026Results posted

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

A Phase 3 interventional study of Lebrikizumab in Atopic Dermatitis and Eczema, sponsored by Almirall, S.A.. Completed at 33 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
11th of 24
260 · median 252
Started
2023
with 3 others
Phase 3
17 of 24
2 open now
Registered
17th of 24
by date
Lead sponsor
5 of 24
Almirall, S.A.

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 11th largest by enrollment, is one of 4 that started in 2023, is one of 17 in phase 3, and was the 17th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis
  • Eczema

Keywords

  • Dermatitis
  • Skin Diseases
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults and adolescents (aged >=12 to less than [\<] 18 years at the time of form (ICF)/informed assent form (IAF) signature and weighing >=40 kg) who are candidates for systemic AD therapy.
  • Chronic AD that has been present for >=1 year before the Screening visit.
  • EASI score >=12 at the Day 1/Baseline Visit.
  • IGA score >=3 (moderate) (scale of 0 [clear] to 4 [severe]) at the Baseline visit.
  • >=10% BSA of AD involvement at the Day 1/Baseline visit.
  • History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.
  • Completed electronic diary (eDiary) entries for pruritus and sleep-loss for a minimum of 4 of 7 days before Day 1/Baseline.
  • Willing and able to comply with all clinic visits and study-related procedures and questionnaires.
  • For women of : agree to remain abstinent (refrain from heterosexual intercourse) or to use a highly effective method during the treatment period and for at least 4 weeks or 1 menstrual period after the last dose of lebrikizumab.
  • Participant must provide signed ICF. Adolescent participants must also provide separate informed assent to enroll in the study and sign and date either a separate IAF or the ICF signed by the parent/legal guardian (as appropriate based on local regulations and requirements).

Exclusion criteria

Exclusion Criteria:

  • Prior treatment at any time with tralokinumab, lebrikizumab, or an oral JAK inhibitor.
  • Intention to use any concomitant medication or therapy that is not permitted by this protocol or failure to undergo the required for a particular prohibited medication.
  • History of anaphylaxis as defined by the Sampson criteria.
  • Uncontrolled chronic disease that might require bursts of oral , example, co-morbid severe uncontrolled asthma (defined by an Asthma Control Questionnaire-5 score >=1.5 or a history of >=2 asthma exacerbations within the last 12 months requiring systemic [oral and/or parenteral] corticosteroid treatment or hospitalisation for >24 hours).
  • Occurrence of the following types of infection within 3 months of Screening or develop any of these infections before Day 1/Baseline:

    1. Serious (requiring hospitalisation, and/or IV or equivalent oral antibiotic treatment, as per the Investigator's opinion);
    2. Opportunistic
    3. Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer);
    4. Recurring (including, but not limited to herpes simplex, herpes zoster, recurring cellulitis, chronic osteomyelitis).
  • Known current or chronic infection with virus.
  • Known liver cirrhosis and/or chronic hepatitis of any aetiology.
  • Known active endoparasitic infections or at high risk of these infections.
  • Known or suspected history of , including history of invasive opportunistic infections (example, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per the Investigator's judgement.
  • History of (HIV) infection or known positive HIV serology.
  • Any laboratory test results from the chemistry or haematology tests obtained at the Screening visit that would jeopardise the patient's participation in the study, per the Investigator's judgement.
  • Presence of skin comorbidities that may interfere with study assessments.
  • History of , including mycosis fungoides, within 5 years before the Screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks.
  • Severe concomitant illness(es) that in the Investigator's judgement would adversely affect the participation in the study. Any other medical or psychological condition that in the opinion of the Investigator may suggest a new and/or insufficiently understood disease, may present an unreasonable risk to the study participant because of his/her participation in this clinical trial, may make participation unreliable, or may interfere with study assessments.
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Lebrikizumab

    Participants will receive loading doses of lebrikizumab 500 milligrams (mg) subcutaneous (SC) injection at Day 1 and Week 2 followed by lebrikizumab 250 mg SC injection, every two weeks (Q2W) from Week 4 to Week 16. At Week 16, the dosing frequency will be reduced to every 4 weeks (Q4W) and will receive lebrikizumab 250 mg SC injection for up to Week 24, last dose of study medication is administered at Week 20.

    Biological: Lebrikizumab

Interventions

  • BiologicalLebrikizumab

    Lebrikizumab solution for injection administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24

    The EASI is used to assess the severity and extent of AD; it is a composite index with total score ranging from 0 to 72, with higher values indicating more severe and extensive disease. The severity of erythema, induration/papulation, excoriation, and lichenification will be assessed by the Investigator or trained designee on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. In addition, the extent of AD involvement in each of the 4 body areas will be assessed as a percentage by body area of head/neck, trunk, upper limbs, and lower limbs, and converted to a score of 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Percentage of participants who achieved EASI total \<= 7 at Week 24 was reported.

    Time frame: At Week 24

Secondary outcomes

  1. Percentage of Participants Who Achieved EASI Total Score <=7, EASI <=5, and EASI <=3 by Visit

    The EASI is used to assess the severity and extent of AD; it is a composite index with total score ranging from 0 to 72, with higher values indicating more severe and extensive disease. The severity of erythema, induration/papulation, excoriation, and lichenification will be assessed by the Investigator or trained designee on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. In addition, the extent of AD involvement in each of the 4 body areas will be assessed as a percentage by body area of head/neck, trunk, upper limbs, and lower limbs, and converted to a score of 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Percentage of participants who achieved EASI Total Score \<=7, EASI \<=5, and EASI \<=3 at each visit was reported.

    Time frame: At Weeks 2, 4, 16, and 24

  2. Percentage of Participants Who Achieved EASI 75 and EASI 90 by Visit

    The EASI is used to assess the severity and extent of AD; it is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and or extensive disease. EASI 75 is defined as 75% reduction from baseline in the EASI score. EASI 90 is defined as 90% reduction from baseline in the EASI score. Percentage of participants who achieved EASI 75 and EASI 90 at each visit was reported.

    Time frame: At Weeks 2, 4, 16 and 24

  3. Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction Greater Than or Equal to (>=2) Points From Baseline by Visit

    The IGA is an instrument used to globally rate the severity of the participant's AD. It is based on a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe), and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting (minimal, palpable induration and significant induration). Percentage of participants with an IGA Score of 0 or 1 and a reduction \>=2 points from baseline at each visit was reported.

    Time frame: At Weeks 2, 4, 16 and 24

  4. Percentage of Participants Who Achieved Scoring Atopic Dermatitis (SCORAD) 75 and SCORAD 90 by Visit

    SCORAD is a validated clinical tool for assessing the extent and intensity of AD. There are 3 components: surface involvement, intensity part and subjective assessment. Surface involvement is assessed as proportion of involved surface area segment by segment by applying the rule of 9s. Intensity part of the SCORAD consists of 6 items: erythema, oedema, oozing/crusting, excoriation, lichenification, and dryness. Each item is graded as follows: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points). Subjective assessment of itch and of sleeplessness is recorded for each symptom using a VAS, where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), for maximum possible score of 20. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition. SCORAD 75 is defined as 75% reduction in SCORAD from baseline. SCORAD 90 is defined as 90% reduction in SCORAD from baseline.

    Time frame: At Week 2, 4, 16 and 24

  5. Percentage Change From Baseline in Modified Total Lesion Symptom Score (mTLSS) (Hands) From Baseline by Visit

    mTLSS combines an evaluation of hand eczema lesions severity including 6 key signs (erythema, desquamation, lichenification/hyperkeratosis, vesiculae, oedema, fissures) and the intensity of pruritus and pain. The seven features of AD of the hands (erythema, scaling, lichenification/hyperkeratosis, vesiculation, oedema, fissures, pruritus/pain) form the composite scale of mTLSS' strength and each one of them scores from (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 21 (more serious disease). Percentage change from baseline was calculated as: (\[Observed or imputed value at post-baseline time point (i.e. Visit) - Observed value at Baseline\]/Observed value at Baseline) \*100.

    Time frame: Baseline, Week 2, 4, 16, and 24

  6. Percentage of Participants With Pruritus Numerical Rating Scale (NRS) >=4 at Baseline Who Achieved >=4-Point Improvement in Pruritus NRS From Baseline by Visit

    The Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity score over the past 24 hours, with 0 (No itch) to 10 (Worst itch imaginable). Assessments will be recorded by the participant using an eDiary. Percentage of participants with pruritus NRS \>=4 at baseline who achieved \>=4-Point improvement in pruritus NRS from baseline at each visit was reported

    Time frame: At Weeks 2, 4, 16 and 24

  7. Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) 0-1 by Visit

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicates 0-1 (no effect on patient's life), 2-5 (small effect on patient's life), 6-10 (moderate effect on patient's life), 11-20 (very large effect on patient's life), 21-30 (extremely large effect on patient's life). Percentage of participants who achieved DLQI 0-1 at each visit was reported.

    Time frame: At Weeks 2, 4, 16 and 24

  8. Percentage of Participants With DLQI >=4 at Baseline Who Achieved >=4-Point Improvement in DLQI From Baseline by Visit

    DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. High score is indicative of a poor QoL. Percentage of participants with DLQI \>=4 at Baseline who achieved \>=4-Point improvement in DLQI from baseline at each visit was reported.

    Time frame: At Weeks 2, 4, 16 and 24

  9. Percentage of Participants Who Achieved Children Dermatology Life Quality Index (cDLQI) 0-1 by Visit

    cDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI. The answers to the questions are generally scored on a 4-point scale from 0=not at all or question unanswered, 1=only a little, 2=quite a lot, 3=very much. cDLQI is calculated by summing the score of each question resulting in 0 to 30. Higher the score, the more impairment of the child's life is experienced. Percentage of participants who achieved cDLQI 0-1 at each visit was reported.

    Time frame: At Weeks 2, 4, 16 and 24

  10. Percentage of Participants With cDLQI >=6 at Baseline Who Achieved >=6-Point Improvement in cDLQI From Baseline by Visit

    cDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI. The answers to the questions are generally scored on a 4-point scale from 0=not at all or question unanswered, 1=only a little, 2=quite a lot, 3=very much. cDLQI is calculated by summing the score of each question resulting in 0 to 30. Higher the score, the more impairment of the child's life is experienced. Percentage of participants with cDLQI \>=6 at baseline who achieved \>=6-Point improvement in cDLQI from baseline at each visit was reported.

    Time frame: At Week 2, 4, 16 and 24

  11. Percentage of Participants With a Sleep-Loss Scale of >=2 Points at Baseline Who Achieved at Least 2-point Reduction From Baseline by Visit

    Sleep loss will be assessed by all participants using a patient-related outcome (PRO) instrument. Participants (and if applicable, with help of parents/caregiver if required) will rate their sleep on a 5-point Likert scale (with scores ranging from 0 \[not at all\] to 4 \[unable to sleep at all\]). Assessments will be recorded by the participant using an eDiary.The baseline Sleep-Loss Scale score will be determined based on the average of daily Sleep-Loss Scale scores during the 7 days immediately before the Day 1 or Baseline visit. Percentage of participants with a Sleep-Loss scale of \>=2 points at baseline who achieved at least 2-point reduction from baseline at each visit was reported.

    Time frame: At Weeks 2, 4, 16 and 24

  12. Percentage of Participants With Patient-Oriented Eczema Measure (POEM) >=4 at Baseline Who Achieved >=4-Point Improvement in POEM From Baseline by Visit

    The POEM is a 7-item, validated questionnaire completed by the participant (and, if applicable, with help of parents/caregiver if required) to assess disease symptoms. Participants are asked to respond to questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping. All answers carry equal weight, with a total possible score ranging from 0 to 28 (answers scored as: No days = 0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; every day = 4. A high score is indicative of a poor quality of life. POEM responses are captured weekly using an eDiary. Percentage of participants with POEM \>=4 at baseline who achieved \>=4-Point improvement in POEM from baseline at each visit was reported.

    Time frame: At Weeks 2, 4, 16 and 24

  13. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related TEAEs, TEAEs Leading to Study Treatment Discontinuation, and Treatment-emergent Adverse Events of Special Interest (TEAESIs)

    TEAEs are undesirable events that first occurred or worsened in severity after the date of first IMP injection in the study, and on or prior to the date of the last visit within the treatment period. An SAE are AE, which falls into any of the following categories: death, is life-threatening, requires in-patient hospitalisation or prolongs existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect, or any other medically important event that may jeopardise the participant or may require intervention to prevent one of the other above outcomes. Related TEAEs includes events considered related or possibly related to study treatment by the Investigator. The following treatment-emergent AEs are being designated as AESIs: conjunctivitis, herpes simplex or zoster infection and parasitic infections.

    Time frame: Baseline up to follow-up (Week 28)

07

Results

Posted Jul 17, 2026

Participant flow

The study was conducted at 41 sites in Germany, Netherlands and the United Kingdom from 20 November 2023 to 25 June 2025.

Participant flow — Overall Study
MilestoneLebrikizumab
Started260
Modified full analysis set (mfas)247
Completed243
Not completed17
Withdrew: Adverse event5
Withdrew: Lost to follow-up1
Withdrew: Physician decision2
Withdrew: Protocol deviation4
Withdrew: Withdrawal by subject5

Outcome measures

PrimaryPercentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24

The EASI is used to assess the severity and extent of AD; it is a composite index with total score ranging from 0 to 72, with higher values indicating more severe and extensive disease. The severity of erythema, induration/papulation, excoriation, and lichenification will be assessed by the Investigator or trained designee on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. In addition, the extent of AD involvement in each of the 4 body areas will be assessed as a percentage by body area of head/neck, trunk, upper limbs, and lower limbs, and converted to a score of 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Percentage of participants who achieved EASI total \<= 7 at Week 24 was reported.

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24
Percentage of participantsLebrikizumab
Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 2474.7 (69.2 to 80.3)
SecondaryPercentage of Participants Who Achieved EASI Total Score <=7, EASI <=5, and EASI <=3 by Visit

The EASI is used to assess the severity and extent of AD; it is a composite index with total score ranging from 0 to 72, with higher values indicating more severe and extensive disease. The severity of erythema, induration/papulation, excoriation, and lichenification will be assessed by the Investigator or trained designee on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. In addition, the extent of AD involvement in each of the 4 body areas will be assessed as a percentage by body area of head/neck, trunk, upper limbs, and lower limbs, and converted to a score of 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Percentage of participants who achieved EASI Total Score \<=7, EASI \<=5, and EASI \<=3 at each visit was reported.

Time frame:
At Weeks 2, 4, 16, and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved EASI Total Score <=7, EASI <=5, and EASI <=3 by Visit
Percentage of participantsLebrikizumab
EASI Total Score <=7: At Week 213.4 (9.1 to 17.6)
EASI Total Score <=7: At Week 435.9 (29.9 to 41.9)
EASI Total Score <=7: At Week 1670.6 (64.7 to 76.4)
EASI Total Score <=5: At Week 28.1 (4.7 to 11.5)
EASI Total Score <=5: At Week 422.8 (17.6 to 28.1)
EASI Total Score <=5: At Week 1655.1 (48.7 to 61.4)
EASI Total Score <=5: At Week 2463.0 (56.8 to 69.1)
EASI Total Score <=3: At Week 23.2 (1.0 to 5.4)
EASI Total Score <=3: At Week 411.4 (7.4 to 15.4)
EASI Total Score <=3: At Week 1633.7 (27.8 to 39.6)
EASI Total Score <=3: At Week 2443.8 (37.4 to 50.1)
SecondaryPercentage of Participants Who Achieved EASI 75 and EASI 90 by Visit

The EASI is used to assess the severity and extent of AD; it is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and or extensive disease. EASI 75 is defined as 75% reduction from baseline in the EASI score. EASI 90 is defined as 90% reduction from baseline in the EASI score. Percentage of participants who achieved EASI 75 and EASI 90 at each visit was reported.

Time frame:
At Weeks 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved EASI 75 and EASI 90 by Visit
Percentage of participantsLebrikizumab
EASI 75: At Week 27.7 (4.4 to 11.1)
EASI 75: At Week 421.4 (16.2 to 26.5)
EASI 75: At Week 1658.7 (52.4 to 65.0)
EASI 75: At Week 2463.5 (57.4 to 69.7)
EASI 90: At Week 21.2 (0.0 to 2.6)
EASI 90: At Week 45.3 (2.5 to 8.1)
EASI 90: At Week 1623.1 (17.8 to 28.4)
EASI 90: At Week 2434.1 (28.1 to 40.1)
SecondaryPercentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction Greater Than or Equal to (>=2) Points From Baseline by Visit

The IGA is an instrument used to globally rate the severity of the participant's AD. It is based on a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe), and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting (minimal, palpable induration and significant induration). Percentage of participants with an IGA Score of 0 or 1 and a reduction \>=2 points from baseline at each visit was reported.

Time frame:
At Weeks 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction Greater Than or Equal to (>=2) Points From Baseline by Visit
Percentage of participantsLebrikizumab
At Week 24.9 (2.2 to 7.5)
At Week 411.0 (7.1 to 14.9)
At Week 1632.3 (26.3 to 38.2)
At Week 2441.3 (35.1 to 47.6)
SecondaryPercentage of Participants Who Achieved Scoring Atopic Dermatitis (SCORAD) 75 and SCORAD 90 by Visit

SCORAD is a validated clinical tool for assessing the extent and intensity of AD. There are 3 components: surface involvement, intensity part and subjective assessment. Surface involvement is assessed as proportion of involved surface area segment by segment by applying the rule of 9s. Intensity part of the SCORAD consists of 6 items: erythema, oedema, oozing/crusting, excoriation, lichenification, and dryness. Each item is graded as follows: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points). Subjective assessment of itch and of sleeplessness is recorded for each symptom using a VAS, where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), for maximum possible score of 20. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition. SCORAD 75 is defined as 75% reduction in SCORAD from baseline. SCORAD 90 is defined as 90% reduction in SCORAD from baseline.

Time frame:
At Week 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Scoring Atopic Dermatitis (SCORAD) 75 and SCORAD 90 by Visit
Percentage of participantsLebrikizumab
SCORAD 75: At Week 20.1 (0.0 to 0.5)
SCORAD 75: At Week 42.0 (0.0 to 4.2)
SCORAD 75: At Week 169.1 (4.5 to 13.6)
SCORAD 75: At Week 2420.4 (13.8 to 27.0)
SCORAD 90: At Week 20 (0.0 to 0.0)
SCORAD 90: At Week 40.6 (0.0 to 1.7)
SCORAD 90: At Week 160.9 (0.0 to 2.5)
SCORAD 90: At Week 243.4 (0.5 to 6.2)
SecondaryPercentage Change From Baseline in Modified Total Lesion Symptom Score (mTLSS) (Hands) From Baseline by Visit

mTLSS combines an evaluation of hand eczema lesions severity including 6 key signs (erythema, desquamation, lichenification/hyperkeratosis, vesiculae, oedema, fissures) and the intensity of pruritus and pain. The seven features of AD of the hands (erythema, scaling, lichenification/hyperkeratosis, vesiculation, oedema, fissures, pruritus/pain) form the composite scale of mTLSS' strength and each one of them scores from (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 21 (more serious disease). Percentage change from baseline was calculated as: (\[Observed or imputed value at post-baseline time point (i.e. Visit) - Observed value at Baseline\]/Observed value at Baseline) \*100.

Time frame:
Baseline, Week 2, 4, 16, and 24
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Modified Total Lesion Symptom Score (mTLSS) (Hands) From Baseline by Visit
Percentage changeLebrikizumab
Baseline9.7 ± 0.32
Percent change at Week 2-20.6 ± 3.16
Percent change at Week 4-37.9 ± 2.78
Percent change at Week 16-62.1 ± 3.02
Percent change at Week 24-66.3 ± 2.86
SecondaryPercentage of Participants With Pruritus Numerical Rating Scale (NRS) >=4 at Baseline Who Achieved >=4-Point Improvement in Pruritus NRS From Baseline by Visit

The Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity score over the past 24 hours, with 0 (No itch) to 10 (Worst itch imaginable). Assessments will be recorded by the participant using an eDiary. Percentage of participants with pruritus NRS \>=4 at baseline who achieved \>=4-Point improvement in pruritus NRS from baseline at each visit was reported

Time frame:
At Weeks 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Pruritus Numerical Rating Scale (NRS) >=4 at Baseline Who Achieved >=4-Point Improvement in Pruritus NRS From Baseline by Visit
Percentage of participantsLebrikizumab
At Week 26.0 (2.9 to 9.1)
At Week 422.4 (16.8 to 27.9)
At Week 1650.9 (43.5 to 58.3)
At Week 2447.3 (40.0 to 54.5)
SecondaryPercentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) 0-1 by Visit

The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicates 0-1 (no effect on patient's life), 2-5 (small effect on patient's life), 6-10 (moderate effect on patient's life), 11-20 (very large effect on patient's life), 21-30 (extremely large effect on patient's life). Percentage of participants who achieved DLQI 0-1 at each visit was reported.

Time frame:
At Weeks 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) 0-1 by Visit
Percentage of participantsLebrikizumab
DLQI 0 or 1 at Week 24.4 (1.7 to 7.1)
DLQI 0 or 1 at Week 412.1 (7.8 to 16.4)
DLQI 0 or 1 at Week 1629.9 (23.9 to 36.0)
DLQI 0 or 1 at Week 2421.4 (15.7 to 27.2)
SecondaryPercentage of Participants With DLQI >=4 at Baseline Who Achieved >=4-Point Improvement in DLQI From Baseline by Visit

DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. High score is indicative of a poor QoL. Percentage of participants with DLQI \>=4 at Baseline who achieved \>=4-Point improvement in DLQI from baseline at each visit was reported.

Time frame:
At Weeks 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With DLQI >=4 at Baseline Who Achieved >=4-Point Improvement in DLQI From Baseline by Visit
Percentage of participantsLebrikizumab
At Week 255.6 (48.4 to 62.8)
At Week 473.0 (66.4 to 79.5)
At Week 1684.8 (79.1 to 90.5)
At Week 2481.4 (75.2 to 87.6)
SecondaryPercentage of Participants Who Achieved Children Dermatology Life Quality Index (cDLQI) 0-1 by Visit

cDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI. The answers to the questions are generally scored on a 4-point scale from 0=not at all or question unanswered, 1=only a little, 2=quite a lot, 3=very much. cDLQI is calculated by summing the score of each question resulting in 0 to 30. Higher the score, the more impairment of the child's life is experienced. Percentage of participants who achieved cDLQI 0-1 at each visit was reported.

Time frame:
At Weeks 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Children Dermatology Life Quality Index (cDLQI) 0-1 by Visit
Percentage of participantsLebrikizumab
cDLQI 0 or 1 at Week 20.3 (0.0 to 5.0)
cDLQI 0 or 1 at Week 44.0 (0.0 to 20.2)
cDLQI 0 or 1 at Week 1611.0 (0.0 to 30.3)
cDLQI 0 or 1 at Week 2430.7 (3.5 to 57.9)
SecondaryPercentage of Participants With cDLQI >=6 at Baseline Who Achieved >=6-Point Improvement in cDLQI From Baseline by Visit

cDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI. The answers to the questions are generally scored on a 4-point scale from 0=not at all or question unanswered, 1=only a little, 2=quite a lot, 3=very much. cDLQI is calculated by summing the score of each question resulting in 0 to 30. Higher the score, the more impairment of the child's life is experienced. Percentage of participants with cDLQI \>=6 at baseline who achieved \>=6-Point improvement in cDLQI from baseline at each visit was reported.

Time frame:
At Week 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With cDLQI >=6 at Baseline Who Achieved >=6-Point Improvement in cDLQI From Baseline by Visit
Percentage of participantsLebrikizumab
At Week 244.4 (12.0 to 76.9)
At Week 464.0 (31.3 to 96.7)
At Week 1652.4 (18.4 to 86.5)
At Week 2466.2 (35.0 to 97.4)
SecondaryPercentage of Participants With a Sleep-Loss Scale of >=2 Points at Baseline Who Achieved at Least 2-point Reduction From Baseline by Visit

Sleep loss will be assessed by all participants using a patient-related outcome (PRO) instrument. Participants (and if applicable, with help of parents/caregiver if required) will rate their sleep on a 5-point Likert scale (with scores ranging from 0 \[not at all\] to 4 \[unable to sleep at all\]). Assessments will be recorded by the participant using an eDiary.The baseline Sleep-Loss Scale score will be determined based on the average of daily Sleep-Loss Scale scores during the 7 days immediately before the Day 1 or Baseline visit. Percentage of participants with a Sleep-Loss scale of \>=2 points at baseline who achieved at least 2-point reduction from baseline at each visit was reported.

Time frame:
At Weeks 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a Sleep-Loss Scale of >=2 Points at Baseline Who Achieved at Least 2-point Reduction From Baseline by Visit
Percentage of participantsLebrikizumab
At Week 22.8 (0.0 to 6.0)
At Week 426.1 (17.6 to 34.5)
At Week 1633.9 (23.9 to 43.8)
At Week 2436.2 (26.8 to 45.5)
SecondaryPercentage of Participants With Patient-Oriented Eczema Measure (POEM) >=4 at Baseline Who Achieved >=4-Point Improvement in POEM From Baseline by Visit

The POEM is a 7-item, validated questionnaire completed by the participant (and, if applicable, with help of parents/caregiver if required) to assess disease symptoms. Participants are asked to respond to questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping. All answers carry equal weight, with a total possible score ranging from 0 to 28 (answers scored as: No days = 0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; every day = 4. A high score is indicative of a poor quality of life. POEM responses are captured weekly using an eDiary. Percentage of participants with POEM \>=4 at baseline who achieved \>=4-Point improvement in POEM from baseline at each visit was reported.

Time frame:
At Weeks 2, 4, 16 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Patient-Oriented Eczema Measure (POEM) >=4 at Baseline Who Achieved >=4-Point Improvement in POEM From Baseline by Visit
Percentage of participantsLebrikizumab
At Week 246.1 (39.0 to 53.3)
At Week 479.8 (74.0 to 85.6)
At Week 1689.7 (85.1 to 94.3)
At Week 2487.9 (82.5 to 93.2)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related TEAEs, TEAEs Leading to Study Treatment Discontinuation, and Treatment-emergent Adverse Events of Special Interest (TEAESIs)

TEAEs are undesirable events that first occurred or worsened in severity after the date of first IMP injection in the study, and on or prior to the date of the last visit within the treatment period. An SAE are AE, which falls into any of the following categories: death, is life-threatening, requires in-patient hospitalisation or prolongs existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect, or any other medically important event that may jeopardise the participant or may require intervention to prevent one of the other above outcomes. Related TEAEs includes events considered related or possibly related to study treatment by the Investigator. The following treatment-emergent AEs are being designated as AESIs: conjunctivitis, herpes simplex or zoster infection and parasitic infections.

Time frame:
Baseline up to follow-up (Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related TEAEs, TEAEs Leading to Study Treatment Discontinuation, and Treatment-emergent Adverse Events of Special Interest (TEAESIs)
ParticipantsLebrikizumab
Participants with at least one TEAE204
Participants with at least one SAE7
Participants with at least one related TEAE131
Participants with at least one TEAE leading to treatment discontinuation6
Participants with at least one TEAESI70

Adverse events

Collected over Baseline up to follow-up (Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lebrikizumab0/260 (0%)7/260 (2.7%)127/260 (48.8%)
Most frequent serious events
Most frequent serious events
EventLebrikizumab
Dermatitis atopicSkin and subcutaneous tissue disorders1/260
Erythrodermic atopic dermatitisSkin and subcutaneous tissue disorders1/260
Mitral valve prolapseCardiac disorders1/260
Anal fistulaGastrointestinal disorders1/260
Chest discomfortGeneral disorders1/260
Herpes simplexInfections and infestations1/260
Staphylococcal skin infectionInfections and infestations1/260
Tendon ruptureInjury, poisoning and procedural complications1/260
EndometriosisReproductive system and breast disorders1/260
Most frequent other events
Most frequent other events
EventLebrikizumab
NasopharyngitisInfections and infestations66/260
ConjunctivitisInfections and infestations46/260
Dermatitis atopicSkin and subcutaneous tissue disorders30/260
HeadacheNervous system disorders19/260
Dry eyeEye disorders18/260

Baseline characteristics

Full Analysis Set (FAS) included all enrolled participants.

Age, Continuous
Age, Continuous(years)Lebrikizumab
Mean32.9 ± 14.10
Sex: Female, Male
Sex: Female, Male(Participants)Lebrikizumab
Female106
Male154
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lebrikizumab
Hispanic or Latino2
Not Hispanic or Latino239
Unknown or Not Reported19
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lebrikizumab
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American1
White230
More than one race11
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Lebrikizumab
Netherlands8
United Kingdom34
Germany218
08

Study locations

33 sites
  • Site 34
    Augsburg, Germany
  • Site 9
    Berlin, Germany
  • Site 29
    Bonn, Germany
  • Site 27
    Dresden, Germany
  • Site 28
    Düsseldorf, Germany
  • Site 11
    Erlangen, Germany
  • Site 37
    Frankfurt, Germany
  • Site 32
    Freiburg im Breisgau, Germany
  • Site 5
    Göttingen, Germany
  • Site 15
    Hamburg, Germany
  • Site 3
    Hamburg, Germany
  • Site 8
    Hamburg, Germany
  • Site 23
    Heidelberg, Germany
  • Site 1
    Kiel, Germany
  • Site 19
    Langenau, Germany
  • Site 10
    Lübeck, Germany
  • Site 26
    Mainz, Germany
  • Site 6
    Mannheim, Germany
  • Site 36
    Marburg, Germany
  • Site 13
    München, Germany
  • Site 17
    München, Germany
  • Site 33
    München, Germany
  • Site 4
    Münster, Germany
  • Site 12
    Oberhausen, Germany
  • Site 22
    Oldenburg, Germany
  • Site 2
    Potsdam, Germany
  • Site 30
    Regensburg, Germany
  • Site 7
    Rostock, Germany
  • Site 18
    Tübingen, Germany
  • Site 35
    Bergen op Zoom, Netherlands
  • Site 41
    Utrecht, Netherlands
  • Site 38
    Leeds, United Kingdom
  • Site 14
    York, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2025, 19 months.

Results were first posted in Jul 2026, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 19 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 14, 2023
StartActual
Nov 20, 2023
Primary completionActual
Jun 25, 2025
CompletionActual
Jun 25, 2025
Results first posted
Jul 17, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05990725
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Nov 20, 2023
Primary completion
Jun 25, 2025
Completion
Jun 25, 2025
Results posted
Jul 17, 2026
Last update
Jul 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion